DOCSLIB.ORG

Novel Isosteviol Derivatives As Potential Anticancer Agents

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Novel Isosteviol Derivatives as Potential Anticancer Agents A dissertation presented to the faculty of the College of Arts and Sciences of Ohio University In partial fulfillment of the requirements for the degree Doctor of Philosophy Rumita Laha May 2018 ©2018 Rumita Laha. All Rights Reserved. 2 This dissertation titled Novel Isosteviol Derivatives as Potential Anticancer Agents by RUMITA LAHA has been approved for the Department of Chemistry and Biochemistry and the College of Arts and Sciences by Stephen C. Bergmeier Professor of Chemistry and Biochemistry Robert Frank Dean, College of Arts and Sciences 3 ABSTRACT LAHA, RUMITA, Ph.D., May 2018, Chemistry Novel Isosteviol Derivatives as Potential Anticancer Agents Director of Dissertation: Stephen C. Bergmeier Diterpenes are natural products that provide an interesting lead for anticancer drug discovery. For our studies the readily available diterpene Steviol was used. Our research group has an interest in making diterpene analogs using stevioside as starting material and tests them for cytotoxic activity against various cancer cell lines. The tetracyclic-diterpenoid isosteviol (ent-16-ketobeyeran-19-oic acid) was obtained in large quantity from the acid hydrolysis of steviol glycosides. We used isosteviol to prepare novel structural derivatives in parallel fashion. These analogs were assayed in a number of cancer cell lines in order to identify new anticancer agents. Our prime goal in this dissertation is to show how natural product with pre-existing chiral centers can be used for the synthesis of unique small molecule libraries. We also discussed how these libraries can be further optimized for the discovery of new therapeutics. 4 ACKNOWLEDGMENTS First and foremost, I would like to express my deepest appreciation to my academic advisor Prof. Stephen C. Bergmeier for his mentorship, guidance, and encouragements during my study and research at Ohio University. Without his consistent support, the dissertation would not have been possible. I would also like to thank the members of my dissertation committee, Prof. Jennifer Hines, Prof. Michael Held and Prof. Douglas Goetz for their time and advice. It is my great pleasure to work with such wonderful research group members. I would like to acknowledge both former members and present members for their suggestions and help. They are Dr. Fang Fang, Dr. Susann Krake, Dr. Gregg Wells, Dr. Alicia Frantz, Dr. Dennis Roberts, Dr. Zilong Zheng, Ian Armstrong, Eric Parsons, Liyi Wang and Reaz Uddin. I would also like to thank Prof. John Kopchick and his group member Dr. Reetobrata Basu for the collaboration in testing the cytotoxic activities of isosteviol analogs. Again, I would like to express my special thanks to Prof. Jennifer Hines for giving me so many opportunities to learn computer modeling in her lab. Finally, I would like to dedicate this dissertation to my parents and my dear husband for their love, continuous support and encouragement, and to my brother for his unconditional love and support. Last but not the least, I would love to mention my daughter little Rani whose dazzling smile and innocent face help me keep walking towards the exciting end of this long journey. 5 TABLE OF CONTENTS Page Abstract ................................................................................................................................3 Acknowledgments ...............................................................................................................4 List of Tables .......................................................................................................................9 List of Figures ....................................................................................................................11 List of Schemes ..................................................................................................................12 Chapter 1: Introduction ......................................................................................................15 1.1 Background and Significance ................................................................................. 15 1.1.1 Discovery of Natural Products as Anticancer Agents ...................................... 15 1.2 Overview of Natural Products Showing Anticancer Activity ................................ 17 1.2.1 Diterpenes as Anticancer Agents ..................................................................... 21 1.2.2 Stevioside ......................................................................................................... 23 1.2.3 Steviol – The Aglycon of Steviol Glycosides .................................................. 25 1.2.4 Structurally Modified Different Steviol Derivatives Induced Anticancer Activity in Various Cancer Cell Lines ...................................................................... 25 1.2.5 Isosteviol and Its Different Structural Motif Induced Cytotoxicity ................. 26 Chapter 2: Synthesis of Different Scaffolds from Isosteviol .............................................28 2.1 Introduction ............................................................................................................. 28 2.2 Isosteviol Synthesis ................................................................................................. 28 2.3 Different Scaffolds from Isosteviol ........................................................................ 30 2.3.1 Synthesis of MOM-protected Diol ................................................................... 32 6 2.3.2 Synthesis of Amino Acid ................................................................................. 33 2.3.3 Synthesis of Lactam ......................................................................................... 38 2.3.4 Synthesis of Ketal ............................................................................................ 44 2.3.5 Synthesis of Lactone and Derivatives .............................................................. 44 2.4 Summary ................................................................................................................. 57 Chapter 3: Synthesis and Biological Assay of Isosteviol Derivatives via Functional Group Modification ......................................................................................................................59 3.1 Introduction ............................................................................................................. 59 3.2 Ester and Carbamate Synthesis ............................................................................... 59 3.3 Bioactivity Results for 1st Generation Compounds in Cancer Cell Lines .............. 61 3.3.1 In Human Lung Cancer Cell Lines (H1299) .................................................... 61 3.3.2 In Human Liver Cancer Cell Lines (HepG2) ................................................... 66 3.4 Second Generation Library Synthesis ..................................................................... 68 3.4.1 Several Examples of Ether Derivatives ........................................................... 72 3.4.2 Additional Examples of Modified Ester and Carbamate Derivatives .............. 75 3.5 Bioactivity Results for 2nd Generation Ester Derivatives in H1299 Cell Lines ...... 76 3.6 Bioactivity Results for 2nd Generation Carbamate Derivatives in H1299 Cell Lines ...................................................................................................................................... 78 3.7 Bioactivity Results for all Ester Derivatives in Melanoma and Melanocytes ........ 81 3.8 Bioactivity Results for all Carbamate Derivatives in Melanoma and Melanocytes 85 3.9 Synthesis of Amide Derivatives ............................................................................. 87 3.9.1 Introduction ...................................................................................................... 87 7 3.9.2 Chemical Synthetic Route ................................................................................ 87 3.10 Bioassays for 1st Generation Amide Derivatives in Melanoma and Melanocytes 89 3.11 Synthesis of 2nd Generation Amide Derivatives ................................................... 90 3.12 Bioassays for 2nd Generation Amide Derivatives in Melanoma and Melanocytes92 3.13 Bioactivity Results for all Amide Derivatives (1st & 2nd generations) in H1299 .. 94 3.14 Summary ............................................................................................................... 96 Chapter 4: Peptidomimetics ...............................................................................................98 4.1 Introduction ............................................................................................................. 98 4.2 Generating Diversity at C-19 of Isosteviol by Means of Ugi Reaction .................. 98 4.3 Synthesis of Peptide Analogs ............................................................................... 100 4.3.1 Model Reactions Tested on Isosteviol ........................................................... 102 4.3.2 Addition of Amino Acid to 4.2 ...................................................................... 103 4.3.3 Synthesis of Dipeptide Analog 4.5 in Single Step ......................................... 103 4.4 Synthesis of Analogs with Three Amino Acid Units ........................................... 105 4.4.1 In Search of Ideal Condition for Synthesis of Analogs with Three Amino Acids ......................................................................................................................
Recommended publications
  • Morpho-Anatomical Study of Stevia Rebaudiana Roots Grown in Vitro and in Vivo

    Morpho-Anatomical Study of Stevia Rebaudiana Roots Grown in Vitro and in Vivo

    Revista Brasileira de Farmacognosia 27 (2017) 34–39 ww w.elsevier.com/locate/bjp Original Article Morpho-anatomical study of Stevia rebaudiana roots grown in vitro and in vivo a a a b c Rafael V. Reis , Talita P.C. Chierrito , Thaila F.O. Silva , Adriana L.M. Albiero , Luiz A. Souza , d a,b a,b,∗ José E. Gonc¸ alves , Arildo J.B. Oliveira , Regina A.C. Gonc¸ alves a Programa de Pós-graduac¸ ão em Ciências Farmacêuticas, Universidade Estadual de Maringá, Maringá, PR, Brazil b Departamento de Farmácia, Universidade Estadual de Maringá, Campus Universitário, Maringá, PR, Brazil c Departamento de Biologia, Universidade Estadual de Maringá, Campus Universitário, Maringá, PR, Brazil d Programa de Mestrado em Promoc¸ ão da Saúde, Centro Universitário de Maringá, Maringá, PR, Brazil a r a b s t r a c t t i c l e i n f o Article history: Stevia rebaudiana (Bertoni) Bertoni, Asteraceae, is used as a food additive because its leaves are a source Received 16 May 2016 of steviol glycosides. There are examples of tissue culture based on micropropagation and phytochemical Accepted 14 August 2016 production of S. rebaudiana leaves but there are few studies on adventitious root culture of S. rebaudiana. Available online 7 October 2016 More than 90% of the plants used in industry are harvested indiscriminately. In order to overcome this situation, the development of methodologies that employ biotechnology, such as root culture, provides Keywords: suitable alternatives for the sustainable use of plants. The aim of this study was to compare morpho- Stevia rebaudiana anatomical transverse sections of S.
  • Nutritional and Medicinal Properties of Stevia Rebaudiana

    Nutritional and Medicinal Properties of Stevia Rebaudiana

    Review Article Curr Res Diabetes Obes J Volume 13 Issue 4 - July 2020 Copyright © All rights are reserved by Fasiha Ahsan DOI: 10.19080/CRDOJ.2020.13.555867 Nutritional and Medicinal Properties of Stevia Rebaudiana Fasiha Ahsan*, Shahid Bashir and Faiz-ul-Hassan Shah University Institute of Diet and Nutritional Sciences, The University of Lahore, Pakistan Submission: June 25, 2020; Published: July 16, 2020 *Corresponding author: Fasiha Ahsan, PhD Scholar, University Institute of Diet and Nutritional Sciences, The University of Lahore, Pakistan Abstract Researches on new molecules with the least toxic effects and better potency is on its way and more attention is being given upon medicinal plants for forcing away the above problems. Medicinal plants have been recognized as potential drug candidates. Stevia, a natural sweetener with medicinal properties and also having nutritional, therapeutic and industrial importance is being used all over the world. Stevia rebaudiana leaves are usually referred to as candy, sweet and honey leaves. Diterpene glycosides are responsible for its high sweetening potential of leaves. The phytochemical properties of bioactive chemicals present in stevia leaves are involves in maintaining the physiological functions of human body. Paper also highlights the importance of nutritional aspects of dried stevia leaves, metabolism of stevia, effects of it consumption on human health and clinical studies related to stevia ingestion. Various medicinal properties of stevia leaves discussed in paper like anti-hyperglycemia, anti-oxidative, hypotensive, nephro-protective, hepato protective, antibacterial and antifungal. Basic purpose of this review to understand the medicinalKeywords: potential Stevia; Diabetes;of stevia and Phytochemicals; its acceptance Medicinal as a significant plant; Steviol;raw material Nutrition; for human Disorders diet.
  • Title 16. Crimes and Offenses Chapter 13. Controlled Substances Article 1

    Title 16. Crimes and Offenses Chapter 13. Controlled Substances Article 1

    TITLE 16. CRIMES AND OFFENSES CHAPTER 13. CONTROLLED SUBSTANCES ARTICLE 1. GENERAL PROVISIONS § 16-13-1. Drug related objects (a) As used in this Code section, the term: (1) "Controlled substance" shall have the same meaning as defined in Article 2 of this chapter, relating to controlled substances. For the purposes of this Code section, the term "controlled substance" shall include marijuana as defined by paragraph (16) of Code Section 16-13-21. (2) "Dangerous drug" shall have the same meaning as defined in Article 3 of this chapter, relating to dangerous drugs. (3) "Drug related object" means any machine, instrument, tool, equipment, contrivance, or device which an average person would reasonably conclude is intended to be used for one or more of the following purposes: (A) To introduce into the human body any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (B) To enhance the effect on the human body of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (C) To conceal any quantity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; or (D) To test the strength, effectiveness, or purity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state. (4) "Knowingly" means having general knowledge that a machine, instrument, tool, item of equipment, contrivance, or device is a drug related object or having reasonable grounds to believe that any such object is or may, to an average person, appear to be a drug related object.
  • Steviol Glycosides from Stevia Rebaudiana Bertoni

    Steviol Glycosides from Stevia Rebaudiana Bertoni

    0 out of 21 Residue Monograph prepared by the meeting of the Joint FAO/WHO Expert Committee on Food Additives (JECFA), 84th meeting 2017 Steviol Glycosides from Stevia rebaudiana Bertoni This monograph was also published in: Compendium of Food Additive Specifications. Joint FAO/WHO Expert Committee on Food Additives (JECFA), 84th meeting 2017. FAO JECFA Monographs 20 © FAO/WHO 2017 1 out of 21 STEVIOL GLYCOSIDES FROM STEVIA REBAUDIANA BERTONI Prepared at the 84th JECFA (2017) and published in FAO JECFA Monographs 20 (2017), superseding tentative specifications prepared at the 82nd JECFA (2016) and published in FAO JECFA Monographs 19 (2016). An ADI of 0 - 4 mg/kg bw (expressed as steviol) was established at the 69th JECFA (2008). SYNONYMS INS No. 960 DEFINITION Steviol glycosides consist of a mixture of compounds containing a steviol backbone conjugated to any number or combination of the principal sugar moieties (glucose, rhamnose, xylose, fructose, arabinose, galactose and deoxyglucose) in any of the orientations occurring in the leaves of Stevia rebaudiana Bertoni. The product is obtained from the leaves of Stevia rebaudiana Bertoni. The leaves are extracted with hot water and the aqueous extract is passed through an adsorption resin to trap and concentrate the component steviol glycosides. The resin is washed with a solvent alcohol to release the glycosides and the product is recrystallized from methanol or aqueous ethanol. Ion exchange resins may be used in the purification process. The final product may be spray-dried. Chemical name See Appendix 1 C.A.S. number See Appendix 1 Chemical formula See Appendix 1 Structural formula Steviol (R1 = R2 = H) is the aglycone of the steviol glycosides.
  • Rapid and Economic Determination of 13 Steviol Glycosides In

    Rapid and Economic Determination of 13 Steviol Glycosides In

    pubs.acs.org/JAFC Article Rapid and Economic Determination of 13 Steviol Glycosides in Market-Available Food, Dietary Supplements, and Ingredients: Single-Laboratory Validation of an HPLC Method Zhiyan Liu, Kangzi Ren, Ye Feng, Tommy Uong, Scott Krepich, and Hong You* Cite This: https://dx.doi.org/10.1021/acs.jafc.0c03453 Read Online ACCESS Metrics & More Article Recommendations *sı Supporting Information ABSTRACT: Steviol glycosides, obtained from leaves of Stevia rebaudiana Bertoni (stevia) or produced via bioconversion and biosynthesis, are diterpenes used by the food/dietary supplement industry as zero-calorie sweeteners derived from natural sources. JECFA 2017 is the most updated international standardized method but it runs for 80 min per sample with suboptimal separations on several critical pairs for its high-performance liquid chromatography-ultraviolet (HPLC-UV) determination. We developed and validated a rapid and economic HPLC-UV method using the superficially porous particle column to determine 13 steviol glycosides (stevioside, dulcoside A, rubusoside, steviobioside, and rebaudioside A−F, I, M, and N). Baseline separation with a minimum resolution of 1.5 for 13 steviol glycosides was achieved within only 14 min of separation time. The hydrocarbon stationary phase with additional steric interactions from the isobutyl side chains on the C18 ligand was shown to be an important contributor to chromatographic selectivity of several critical pairs of steviol glycosides. The method was proven to perform suitably on columns from three different manufacturers and two HPLC instruments. The method was further used to perform a single-lab validation on eight food and supplement products with multiple matrices. The results ranged from 0.05% w/w rebaudioside A for a hard-candy finished product to 100.8% w/w purity for a rebaudioside M raw ingredient.
  • Synthesis and Pharmacological Screening of Novel 1,5

    Synthesis and Pharmacological Screening of Novel 1,5

    Vol 2, Issue 1 , 2014 Review Article STEVIOL GLYCOSIDES AND THEIR USE IN FOOD PROCESSING: A REVIEW ROLLY MEHROTRA*1, DHEER SINGH2, AVINASH TIWARI3 1 PhD Student, Centre for Food Technology, Jiwaji University, Gwalior (MP)., 1 Dean, Institute of Engineering and Technology, Bundelkhand University, Jhansi ³ Reader, department of Botany, Jiwaji University, Gwalior (MP) Email: tiwariavinash2@ gmail.com Received: 29 June 2014, Revised and Accepted: 7 August 2014 ABSTRACT Steviol glycosides are the proteinacious secondary metabolites present in the leaves of Stevia rebaudiana Bertoni. These SG’s are the principal sweetening agents which are 200-300 times more sweeter than sucrose. A number of SG’s are present in the leaves of Stevia namely, stevioside, dulcoside A, rebaudioside A, rebaudioside B, rebaudioside C (previously known as dulcoside B), rebaudioside D, rebaudioside E and steviolbioside, 100–125. At the 63rd meeting a temporary ADI of 0-2 mg/kg bodyweight and day, expressed as steviol, was established based on a No-Observed- Effect-Level (NOEL). Steviol glycoside extracts have broad applications as sweetener in the manufacture of fruit and milk drinks, desserts, yoghurt, delicacies, confectioneries, fruit products, processed seafood products, pickles, table-top sweeteners and dietary supplements. Other aspects considered are physicochemical and biologic properties for food processing, stability and therapeutic value of SG’s. nutritional information, Stevia market and household uses. Keywords: Stevia rebaudiana, Steviol glycosides, stevioside and rebaudioside. INTRODUCTION Stevia rebaudiana, a perennial herb from the Asteraceae family, is dulcoside. The two primary compounds, stevioside and rebaudioside known to the scientific world for its sweetness and steviol glycosides A, use only glucose: stevioside has two linked glucose molecules at (SGs).
  • Identification and Quantification of Major Steviol Glycosides in Stevia

    Identification and Quantification of Major Steviol Glycosides in Stevia

    ARTICLE pubs.acs.org/JAFC Identification and Quantification of Major Steviol Glycosides in Stevia rebaudiana Purified Extracts by 1H NMR Spectroscopy Valerio Pieri,† Andrea Belancic,‡ Susana Morales,‡ and Hermann Stuppner*,† † Institute of Pharmacy/Pharmacognosy, Center for Molecular Biosciences Innsbruck (CMBI), University of Innsbruck, Innrain 52c, 6020 Innsbruck, Austria ‡ Prodalysa Ltda, Lote 13, Parque Industrial Gulmue, Camino Internacional, Concon, Chile bS Supporting Information ABSTRACT: The use of 1H NMR spectroscopy for the characterization of Stevia rebaudiana extracts is presented. The developed method allows qualitative and quantitative determination of the major steviol glycosides in purified extracts and fractions obtained from various stages of the purification process. Moreover, it proved to be a powerful tool to differentiate between glycosides which are naturally occurring in the stevia plant and artifacts formed in the course of the manufacturing process. Identification of steviol glycosides was achieved by the use of 2D NMR techniques, whereas quantification is based on qHNMR using anthracene as internal À standard. The solvent mixture pyridine-d5 DMSO-d6 (6:1) enabled satisfactory separation of the signals to be integrated. Validation of the method was performed in terms of specificity, precision, accuracy, linearity, robustness, and stability. Quantitative results were compared to those obtained with the JECFA HPLCÀUV method and were found to be in reasonable agreement. NMR analysis does not rely on the use of reference compounds and enables significantly faster analysis compared to HPLCÀUV. Thus, NMR represents a feasible alternative to HPLC-based methods for the quality control of Stevia rebaudiana extracts. KEYWORDS: Stevia rebaudiana, steviol glycosides, stevioside, rebaudioside A, qHNMR, quality control ’ INTRODUCTION substitutes” must be substantiated as well.
  • Steviol Glycoside Determination by HPLC with Charged Aerosol and UV Detections Using the Acclaim Trinity P1 Column

    Steviol Glycoside Determination by HPLC with Charged Aerosol and UV Detections Using the Acclaim Trinity P1 Column

    Application Note: 293 Steviol Glycoside Determination by HPLC with Charged Aerosol and UV Detections Using the Acclaim Trinity P1 Column Deanna Hurum and Jeffrey Rohrer; Sunnyvale, CA USA Introduction Steviol glycoside determination is challenging for Key Words In December 2008, the U.S. FDA recognized rebaudioside multiple reasons. The structures of the steviol glycosides are quite similar, differing in small changes in glycosylation. For • Stevia A purified from Stevia rebaudiana (Bertoni) as Generally Recognized as Safe (GRAS) for use as a sugar substitute example, rebaudioside B, an impurity that can be formed • Rebaudioside A in foods.1,2 Since this recognition, stevia products have during processing of the leaves, differs in structure from rebaudioside A primarily by the presence or absence of a • HILIC become popular as table-top and beverage sweeteners. Although the stevia plant and extracts from stevia leaves glucose residue at the R1 position on the terpene (Figure 2). These • Natural have long been used as sweeteners in Asia and Latin structural similarities make chromatographic separation Sweeteners America, the terpene glycosides have different flavor difficult. In addition to the separation challenges, sensitive profiles with both sweet and unpleasant bitter flavors.3 detection of these compounds also can be difficult. They Two steviol glycosides, stevioside and rebaudioside A, are do not absorb strongly in the UV, and typical detection largely responsible for the desired sweet flavor of the leaves wavelengths for steviol glycosides, such as 210 nm, are (Figure 1), with rebaudioside A preferred for sweeteners.4 nonspecific. Other detection methods, such as charged aerosol, can be used in addition to UV detection to improve steviol glycoside quantification.
  • Pharmaceuticals As Environmental Contaminants

    Pharmaceuticals As Environmental Contaminants

    PharmaceuticalsPharmaceuticals asas EnvironmentalEnvironmental Contaminants:Contaminants: anan OverviewOverview ofof thethe ScienceScience Christian G. Daughton, Ph.D. Chief, Environmental Chemistry Branch Environmental Sciences Division National Exposure Research Laboratory Office of Research and Development Environmental Protection Agency Las Vegas, Nevada 89119 [email protected] Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada Why and how do drugs contaminate the environment? What might it all mean? How do we prevent it? Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada This talk presents only a cursory overview of some of the many science issues surrounding the topic of pharmaceuticals as environmental contaminants Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada A Clarification We sometimes loosely (but incorrectly) refer to drugs, medicines, medications, or pharmaceuticals as being the substances that contaminant the environment. The actual environmental contaminants, however, are the active pharmaceutical ingredients – APIs. These terms are all often used interchangeably Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada Office of Research and Development Available: http://www.epa.gov/nerlesd1/chemistry/pharma/image/drawing.pdfNational
  • Photodynamic Therapy for the Treatment of Actinic Keratoses and Other Skin Lesions

    Photodynamic Therapy for the Treatment of Actinic Keratoses and Other Skin Lesions

    Photodynamic Therapy for the Treatment of Actinic Keratoses and Other Skin Lesions Policy Number: Current Effective Date: MM.02.016 March 22, 2019 Lines of Business: Original Effective Date: HMO; PPO; QUEST Integration April 01, 2008 Place of Service: Precertification: Office Not Required I. Description Photodynamic therapy (PDT) refers to light activation of a photosensitizer to generate highly reactive intermediaries, which ultimately cause tissue injury and necrosis. Photosensitizing agents are being proposed for use with dermatologic conditions such as actinic keratoses and nonmelanoma skin cancers.For individuals who have nonhyperkeratotic actinic keratoses on the face or scalp who receive PDT, the evidence includes randomized controlled trials (RCTs). The relevant outcomes are symptoms, change in disease status, quality of life, and treatment-related morbidity. Evidence from multiple RCTs has found that PDT improves the net health outcome in patients with nonhyperkeratotic actinic keratoses on the face or scalp compared with placebo or other active interventions. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome. For individuals who have low-risk basal cell carcinoma who receive PDT, the evidence includes RCTs and systematic reviews of RCTs. The relevant outcomes are symptoms, change in disease status, quality of life, and treatment-related morbidity. Systematic reviews of RCTs have found that PDT may not be as effective as surgery for superficial and nodular basal cell carcinoma. In the small number of trials available, PDT was more effective than placebo. The available evidence from RCTs has suggested that PDT has better cosmetic outcomes than surgery.
  • GRAS Notice 821 for Glucosylated Steviol Glycosides

    GRAS Notice 821 for Glucosylated Steviol Glycosides

    GRAS Notice (GRN) No. 821 https://www.fda.gov/food/generally-recognized-safe-gras/gras-notice-inventory {Ri~(C~ij\;#~[Q) NOV I 9 2018 16 November 20 l 8 OFFICE OF FOOD ADDITIVE SAFETY Dr. Paulette Gaynor Office of Food Additive Safety (HFS-200) Center for Food Safety and Applied Nutrition (CFSAN) Food and Drug Administration 500 l Campus Drive College Park, MD 20740 USA Dear Dr. Gaynor: Re: GRAS Notice for High-Purity Glucosylated Steviol Glycosides In accordance with 21 CFR § 170 Subpart E consisting of§ 170.203 through 170.285, Haigen-BGG Natural Ingredients (HBNI) Limited [l 1038, 11/F, Tower A, Gateway Square No. 18, Xiaguangli, North Road East Third Ring, Chaoyang District, Beijing, China], as the notifier, is submitting one hard copy and one electronic copy (on CD), of all data and information supporting the company's conclusion that high-purity glucosylated steviol glycosides, as manufactured by HBNI, is GRAS under the specified conditions of use as a food ingredient on the basis of scientific procedures, and therefore are not subject to the premarket approval requirements of the Federal Food, Drug and Cosmetic Act. Information setting forth the basis for HBNI's GRAS conclusion, as well as a consensus opinion of an independent panel of experts, also are enclosed for review by the agency. l certify that the enclosed electronic files were scanned for viruses prior to submission and are thus certified as being virus-free using Symantec Endpoint Protection 12.1.5. Should you have any questions or concerns regarding this GRAS notice, please do not hesitate to contact me at any point during the review process so that we may provide a response in a timely manner.
  • GRAS Notice (GRN) No

    GRAS Notice (GRN) No

    GRAS Notice (GRN) No. 715 https://www.fda.gov/Food/IngredientsPackagingLabeling/GRAS/NoticeInventory/default.htm GRAS Notice - Rebaudioside D Blue California 6/26/17 TABLE OF CONTENTS FOREWORD ......................................................................................................................................................................................... 4 PART 1. SIGNED STATEMENTS AND CERTIFICATION ................................................................................................................. 4 A. Basis of Exclusion from the Requirement for Premarket Approval Pursuant to Proposed 21 CFR 170.36(c)(1) ... ........ 4 B. Name and Address of Responsible Party ....................................................................... ................... ............ ................. 5 C. Common Name and Identity of Notified Substance........................................................ .............................................. .. 5 D. Conditions of Intended Use in Food ............................................................................................................................... 5 E. Basis for GRAS Conclusion........................................................................... ................................................................. 6 F. Availability of Information ................................................................................................................................................ 6 PART 2. IDENTITY, METHOD OF MANUFACTURE, SPECIFICATIONS,